About Us
Meet the Team
What we do
Why refer to the National aHUS Service
Why refer to the National C3G Service
Access to Eculizumab for patients with aHUS
Forms and Protocols
Following approval of Eculizumab
Switching to Ravulizumab
Switching patients to biosimilar eculizumab
Public and Patient Interaction
Roadshows and Webinars
NRCTC Annual reports
NRCTC Newsletters
Videos
Clinical research at the NRCTC
SETS aHUS
Frequently Asked Questions
Useful Links
Patients
aHUS
What is AHUS?
Diagnosing aHUS
Treating AHUS
C3G
What is C3G?
Diagnosing C3G
Treating C3G
Clinicians
aHUS for Clinicians
Clinicians: What is aHUS?
Diagnosis of aHUS
STEC-HUS
Genetics of Complement mediated aHUS
Acquired complement mediated aHUS
Diagnostic testing in aHUS
Initial Treatment of Patients with Suspected aHUS
Prophylactic use of Eculizumab in patients with aHUS at time of renal transplantation
Longer term management of patients with aHUS
Shared Care
Data Collection, Patient Review and Counselling
C3G for Clinicians
Clinicians: What is C3G?
Diagnosis of C3G
Differential diagnosis of MPGN and C3G
Pathophysiology of C3G
Acquired Drivers of Dysregulation of Complement in C3G
Genetic Drivers of Dysregulation of Complement in C3G
Diagnostic testing in C3G
Treatment of C3G
C3G Recurrence following Transplantation
Emergency Referrals
Forms and Protocols
Contact Us
Menu
Close
About Us
Patients
Clinicians
Emergency Referrals
Forms and Protocols
Contact Us
Frequently Asked Questions
Skip to content
Open toolbar
Accessibility Tools
Accessibility Tools
Increase Text
Increase Text
Decrease Text
Decrease Text
Grayscale
Grayscale
High Contrast
High Contrast
Negative Contrast
Negative Contrast
Light Background
Light Background
Links Underline
Links Underline
Readable Font
Readable Font
Reset
Reset
